Amlodipine dosage forms and strengths: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Amlodipine}} {{CMG}}; {{AE}} {{AK}} ==3 DOSAGE FORMS AND STRENGTHS== 2.5, 5, and 10 mg Tablets<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = |..." |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==3 | ==3 Dosage Forms and Strengths== | ||
2.5, 5, and 10 mg Tablets<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVASC (AMLODIPINE BESYLATE) TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49#nlm42230-3 | publisher = | date = | accessdate = 6 March 2014 }}</ref> | 2.5, 5, and 10 mg Tablets<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORVASC (AMLODIPINE BESYLATE) TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44e5ad27-e062-461a-bdf4-192d852fbc49#nlm42230-3 | publisher = | date = | accessdate = 6 March 2014 }}</ref> | ||
Revision as of 21:05, 12 March 2014
| Amlodipine |
|---|
| NORVASC®, AMLODIPINE®, AMLODIPINE BESYLATE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Dosage Forms and Strengths |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Amlodipine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
3 Dosage Forms and Strengths
2.5, 5, and 10 mg Tablets[1]
References
- ↑ "NORVASC (AMLODIPINE BESYLATE) TABLET [CARDINAL HEALTH]". Retrieved 6 March 2014.